StockpollyBeta
Get App
Popularity #938
CMPS · NASDAQ · Biotechnology

Compass Pathways (ADR) (CMPS)

Develops COMP360, an investigational psilocybin treatment with psychological support.

$14.83
After hours+0.05 (+0.37%)
At close$14.78(−1.57%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
343839434848504341464352
Research & development222725293332313023302629
131114141516191313161623
General & administrative131114141516191313161623
Other expenses000000004000
Operating income−34−38−39−43−48−48−50−43−41−46−43−52
1645106325−97−51134−201
Interest income002222222124
Interest expense111111111111
Other non-operating income−2−7−5−7−11−7−33−69650−136200
Income before tax−33−32−35−38−38−42−18−38−138−9791−253
Income tax expense000001000−300
Net income from continuing operations−33−33−35−38−39−43−18−38−138−9491−254
Net income−33−33−35−38−39−43−18−38−138−9491−254
EPS, basic−$0.67−$0.53−$0.55−$0.56−$0.56−$0.63−$0.20−$0.41−$1.44−$1.00−$0.42−$2.71
EPS, diluted−$0.67−$0.53−$0.55−$0.56−$0.56−$0.63−$0.24−$0.41−$1.44−$1.00−$0.42−$2.71
Weighted average shares, basic506264686868899395949494
Weighted average shares, diluted506264686868899395949494
EBITDA−32−31−34−37−37−41−16−37−137−9593−252
Depreciation & amortization000000000000
EBIT−32−31−34−37−37−41−16−37−137−9593−252